What is Evommune 's government loans current?

Evommune (EVMN) reported government loans current of $3.61K in Q1 2026.

What does government loans current mean?

This reflects the portion of government-backed or subsidized loans that are due for repayment within the next twelve months. These loans often carry favorable interest rates or specific forgiveness terms tied to research and development activities. Understanding this liability is critical for assessing near-term cash outflows and the impact of public funding on the balance sheet.

Evommune EVMN Government Loans Current

Government Loans Current at other companies

Global PaymentsGPN

$1.58B+34.0%

WestlakeWLK

$496M+12,300%

AppleAAPL

$8.31B-39.1%

FormFactorFORM

$1.15M+2.9%

Advanced Energy IndustriesAEIS

$568.2M—

CACI InternationalCACI

$46.75M-32.0%

Other financials

Income statement

See full

Revenue$1.6M+3.5%

Gross profit$961.1K+10.9%

Operating income-$682.8K-2,027%

Net income-$7.0M-5,414%

EPS (diluted)-$0.36-1,700%

Balance sheet

See full

Cash & equivalents$1.1M+401%

Total debt$2.0M—

Total equity-$4.5M-3,048%

Total assets$7.2M—

Cash flow

See full

Operating cash flow-$424.6K-341%

CapEx$1.0-99.8%

Free cash flow-$2.7M-4,996%

Valuation

See full

Market cap$848.59M+39.5%

Enterprise value$849.52M—

P/S127.3×—

Profitability

See full

Gross margin53.7%—

Operating margin-30.7%—

Net margin-90.1%—

Returns & leverage

See full

Return on equity275.7%—

Debt / equity1.4×—

Current ratio1.2×—

Where this comes from

Reported directly by Evommune in its filing.

Tagged under the XBRL concept meha:GovernmentLoansCurrent.

The official record: Evommune ’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Evommune 's government loans current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Evommune 's government loans current?: Evommune (EVMN) reported government loans current of $3.61K in Q1 2026.
What does government loans current mean?: This reflects the portion of government-backed or subsidized loans that are due for repayment within the next twelve months. These loans often carry favorable interest rates or specific forgiveness terms tied to research and development activities. Understanding this liability is critical for assessing near-term cash outflows and the impact of public funding on the balance sheet.